Timothy Cloughesy - Publications

Affiliations: 
University of California, Los Angeles, Los Angeles, CA 

326 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Nguyen HT, Nguyen N, Liu LY, Dovek L, Lenchner D, Harris R, Ozer B, Ravelo A, Sommer N, Sim MS, Elashoff R, Green R, Nghiemphu PL, Cloughesy TF, Ellingson B, et al. Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. Neuro-Oncology Practice. 6: 103-111. PMID 31386050 DOI: 10.1093/nop/npy021  0.4
2019 Dovek L, Nguyen NT, Ozer BH, Li N, Elashoff RM, Green RM, Liau L, Nghiemphu PL, Cloughesy TF, Lai A. Correlation of commercially available quantitative (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. Neuro-Oncology Practice. 6: 194-202. PMID 31386024 DOI: 10.1093/nop/npy028  0.4
2019 Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, ... ... Cloughesy TF, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism. PMID 31303424 DOI: 10.1016/j.cmet.2019.06.014  0.72
2019 Liu LY, Ji MS, Nguyen NT, Chow FE, Molaie DM, Pianka ST, Green RM, Liau LM, Ellingson BM, Nghiemphu PL, Cloughesy TF, Lai A. Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. Cns Oncology. CNS35. PMID 31293169 DOI: 10.2217/cns-2019-0007  0.68
2019 McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, et al. Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM. Molecular Cancer Therapeutics. PMID 31270152 DOI: 10.1158/1535-7163.MCT-18-1330  0.68
2019 Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, et al. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. PMID 31215634 DOI: 10.1093/neuros/nyz186  0.68
2019 Ventz S, Lai A, Cloughesy TF, Wen PY, Trippa L, Alexander BM. Design and evaluation of an external control arm using prior clinical trials and real-world data. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31175098 DOI: 10.1158/1078-0432.CCR-19-0820  0.4
2019 Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-Oncology. PMID 31066901 DOI: 10.1093/neuonc/noz078  0.68
2019 Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, ... ... Cloughesy T, et al. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal of Neuro-Oncology. PMID 30838489 DOI: 10.1007/s11060-019-03126-x  0.4
2019 Chakhoyan A, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Scientific Reports. 9: 2846. PMID 30808879 DOI: 10.1038/s41598-018-37564-w  0.68
2019 Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. Journal of Neuro-Oncology. PMID 30806888 DOI: 10.1007/s11060-019-03132-z  0.68
2019 Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine. PMID 30742122 DOI: 10.1038/s41591-018-0337-7  0.68
2019 Zhang D, Kim SSR, Kelly DF, Asa SL, Movassaghi M, Mareninov S, Yong WH, Cloughesy TF, Rodriguez FJ, McKeever P, Qian J, Li JY, Mao Q, Newell KL, Green RM, et al. Somatostatin Receptor Ligand Therapy-A Novel Therapy for Neurocytoma. The Journal of Clinical Endocrinology and Metabolism. PMID 30722009 DOI: 10.1210/jc.2018-02419  0.36
2019 Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, ... ... Cloughesy TF, et al. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801207. PMID 30715997 DOI: 10.1200/JCO.18.01207  0.32
2018 Davidson TB, Lee AH, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki AY, Antonios JP, Garcia AJ, Kotecha N, Bayless NL, ... ... Cloughesy TF, et al. Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30498094 DOI: 10.1158/1078-0432.CCR-18-1176  0.68
2018 Yao J, Ruan D, Raymond C, Liau LM, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Improving B Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. Tomography (Ann Arbor, Mich.). 4: 123-137. PMID 30320212 DOI: 10.18383/j.tom.2018.00017  0.68
2018 Smedley NF, Ellingson BM, Cloughesy TF, Hsu W. Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Scientific Reports. 8: 14429. PMID 30258190 DOI: 10.1038/s41598-018-32397-z  0.4
2018 Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Cloughesy TF, et al. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 179. PMID 29958537 DOI: 10.1186/s12967-018-1552-1  0.68
2018 Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, ... ... Cloughesy TF, et al. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo. Neuro-Oncology. PMID 29897562 DOI: 10.1093/neuonc/noy064  0.4
2018 Chakhoyan A, Woodworth DC, Harris RJ, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Ellingson BM. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. Journal of Neuro-Oncology. PMID 29855771 DOI: 10.1007/s11060-018-2910-9  0.68
2018 Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Cloughesy TF, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 142. PMID 29843811 DOI: 10.1186/s12967-018-1507-6  0.68
2018 Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. International Journal of Radiation Oncology, Biology, Physics. 100: 1195-1203. PMID 29722661 DOI: 10.1016/j.ijrobp.2018.01.001  0.68
2018 Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. Journal of Neuro-Oncology. PMID 29679199 DOI: 10.1007/s11060-018-2877-6  0.4
2018 Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP. A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget. 9: 16087-16098. PMID 29662628 DOI: 10.18632/oncotarget.24498  0.4
2018 Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, ... ... Cloughesy TF, et al. Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology. PMID 29660006 DOI: 10.1093/neuonc/noy053  0.4
2018 Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, ... ... Cloughesy TF, et al. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-Oncology. PMID 29660005 DOI: 10.1093/neuonc/noy054  0.4
2018 Harris RJ, Yao J, Chakhoyan A, Raymond C, Leu K, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magnetic Resonance in Medicine. PMID 29626359 DOI: 10.1002/mrm.27204  0.68
2018 Li T, Cox CD, Ozer B, Nguyen NT, Nguyen HN, Lai TJ, Li S, Liu F, Kornblum HI, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. D-2-Hydroxyglutarate is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-induced MIR148A Promoter Methylation. Molecular Cancer Research : McR. PMID 29545476 DOI: 10.1158/1541-7786.MCR-17-0367  0.68
2017 Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. PMID 29266174 DOI: 10.1002/cncr.31172  0.32
2017 Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski N, Taylor J, Clarke JL, Chang SM, et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29074604 DOI: 10.1158/1078-0432.CCR-17-0963  0.32
2017 Ellingson BM, Wen PY, Cloughesy TF. Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma. Neuro-Oncology. PMID 29040703 DOI: 10.1093/neuonc/nox193  0.4
2017 Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncology. PMID 29036345 DOI: 10.1093/neuonc/nox151  0.32
2017 Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, ... ... Cloughesy TF, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nature Medicine. PMID 29035366 DOI: 10.1038/nm.4418  0.72
2017 Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology. PMID 29016998 DOI: 10.1093/neuonc/nox154  0.32
2017 Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, et al. Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio. Neuro-Oncology. PMID 29016943 DOI: 10.1093/neuonc/nox162  0.4
2017 Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, ... ... Cloughesy TF, et al. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology. PMID 28988377 DOI: 10.1007/s11060-017-2624-4  0.4
2017 Chung LK, Pelargos PE, Chan AM, Demos JV, Lagman C, Sheppard JP, Nguyen T, Chang YL, Hojat SA, Prins RM, Liau LM, Nghiemphu L, Lai A, Cloughesy TF, Yong WH, et al. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathology. PMID 28887715 DOI: 10.1007/s10014-017-0300-1  0.68
2017 Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America. PMID 28874539 DOI: 10.1073/pnas.1706689114  0.68
2017 Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28814435 DOI: 10.1158/1078-0432.CCR-17-0764  0.72
2017 Yu A, Faiq N, Green S, Lai A, Green R, Hu J, Cloughesy TF, Mellinghoff I, Nghiemphu PL. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of Neuro-Oncology. PMID 28669012 DOI: 10.1007/s11060-017-2533-6  0.4
2017 Movassaghi M, Shabihkhani M, Hojat SA, Williams RR, Chung LK, Im K, Lucey GM, Wei B, Mareninov S, Wang MW, Ng DW, Tashjian RS, Magaki S, Perez-Rosendahl M, Yang I, ... ... Cloughesy TF, et al. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Experimental and Molecular Pathology. PMID 28663030 DOI: 10.1016/j.yexmp.2017.06.006  0.68
2017 Ellingson BM, Gerstner E, Smits M, Huang RY, Colen RR, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, ... ... Cloughesy TF, et al. Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28655794 DOI: 10.1158/1078-0432.CCR-16-2844  0.4
2017 Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell. PMID 28648777 DOI: 10.1016/j.molcel.2017.05.030  0.72
2017 Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Journal of Neuro-Oncology. PMID 28547590 DOI: 10.1007/s11060-017-2506-9  0.68
2017 Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, ... Cloughesy T, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology. 19: 625-635. PMID 28453751 DOI: 10.1093/neuonc/nox029  0.32
2017 Shabihkhani M, Telesca D, Movassaghi M, Naeini YB, Naeini KM, Hojat SA, Gupta D, Lucey GM, Ontiveros M, Wang MW, Hanna LS, Sanchez DE, Mareninov S, Khanlou N, Vinters HV, ... ... Cloughesy TF, et al. Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. Journal of Neuro-Oncology. PMID 28161760 DOI: 10.1007/s11060-017-2377-0  0.68
2017 Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, et al. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology. PMID 28116649 DOI: 10.1007/s11060-016-2357-9  0.32
2017 Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology. PMID 28115578 DOI: 10.1093/neuonc/now287  0.68
2017 Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 28108885 DOI: 10.1007/s13311-016-0507-6  0.4
2016 Ahn C, White P, Liau LM, Cloughesy TF, Nghiemphu PL. Development of an integrated practice unit: Utilizing a lean approach to impact value of care for brain tumor patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 99. PMID 28152815 DOI: 10.1200/jco.2016.34.7_suppl.99  0.68
2016 Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, ... ... Cloughesy TF, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/j.ccell.2016.09.008  0.72
2016 Harris RJ, Cloughesy TF, Liau LM, Nghiemphu PL, Lai A, Pope WB, Ellingson BM. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. Nmr in Biomedicine. PMID 27717216 DOI: 10.1002/nbm.3611  0.68
2016 Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, ... Cloughesy TF, et al. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials. Neuro-Oncology. PMID 27580889 DOI: 10.1093/neuonc/now187  0.4
2016 Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, et al. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology. PMID 27571882 DOI: 10.1093/neuonc/now189  0.68
2016 Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. Jci Insight. 1. PMID 27453950 DOI: 10.1172/jci.insight.87059  0.68
2016 Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298403 DOI: 10.1200/JCO.2016.68.0926  0.72
2016 Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. 8: 341ra75. PMID 27252174 DOI: 10.1126/scitranslmed.aad9784  0.72
2016 Laks DR, Crisman TJ, Shih MY, Mottahedeh J, Gao F, Sperry J, Garrett MC, Yong WH, Cloughesy TF, Liau LM, Lai A, Coppola G, Kornblum HI. Large-scale assessment of the gliomasphere model system. Neuro-Oncology. PMID 27116978 DOI: 10.1093/neuonc/now045  0.72
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... Cloughesy TF, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/j.ccell.2016.03.012  0.72
2016 Ellingson BM, Nguyen HN, Lai A, Nechifor RE, Zaw O, Pope WB, Yong WH, Nghiemphu PL, Liau LM, Cloughesy TF. Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. Cancer. PMID 26998740 DOI: 10.1002/cncr.29957  0.72
2016 Ab KL, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Journal of Magnetic Resonance Imaging : Jmri. PMID 26971534 DOI: 10.1002/jmri.25227  0.72
2016 Panosyan EH, Lasky JL, Lin HJ, Lai A, Hai Y, Guo X, Quinn M, Nelson SF, Cloughesy TF, Nghiemphu PL. Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. Journal of Neuro-Oncology. PMID 26922345 DOI: 10.1007/s11060-016-2073-5  0.72
2016 Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-Oncology. PMID 26809751 DOI: 10.1093/neuonc/nov300  0.72
2016 Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26786929 DOI: 10.1200/JCO.2015.63.6563  0.72
2015 Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography : a Journal For Imaging Research. 1: 37-43. PMID 26740971 DOI: 10.18383/j.tom.2015.00115  0.4
2015 Banerjee P, Leu K, Harris RJ, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Bookheimer SY, Ellingson BM. Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. Neuroimage. Clinical. 9: 617-24. PMID 26740915 DOI: 10.1016/j.nicl.2015.10.010  0.72
2015 Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. PMID 26588662 DOI: 10.1002/cncr.29798  0.72
2015 Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, Nelson SF, Cloughesy TF, Yong WH, Lai A, Tso CL. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Molecular Cancer. 14: 189. PMID 26546412 DOI: 10.1186/s12943-015-0459-1  0.72
2015 Yong WH, Shabihkhani M, Telesca D, Yang S, Tso JL, Menjivar JC, Wei B, Lucey GM, Mareninov S, Chen Z, Liau LM, Lai A, Nelson SF, Cloughesy TF, Tso CL. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. Plos One. 10: e0141334. PMID 26506620 DOI: 10.1371/journal.pone.0141334  0.72
2015 Huang RY, Rahman R, Ballman KV, Felten S, Anderson K, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26490307 DOI: 10.1158/1078-0432.CCR-14-3040  0.72
2015 Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, ... ... Cloughesy TF, et al. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell. PMID 26455392 DOI: 10.1016/j.molcel.2015.09.002  0.72
2015 Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology. PMID 26449250 DOI: 10.1093/neuonc/nov245  0.72
2015 Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, ... ... Cloughesy TF, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology. 17: 1188-98. PMID 26250565 DOI: 10.1093/neuonc/nov095  0.72
2015 Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, ... ... Cloughesy TF, et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metabolism. PMID 26190651 DOI: 10.1016/j.cmet.2015.06.009  0.4
2015 Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 26170313 DOI: 10.1073/pnas.1511759112  0.72
2015 Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26124478 DOI: 10.1200/JCO.2015.61.5005  0.72
2015 Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology. PMID 26113557 DOI: 10.1093/neuonc/nov106  0.72
2015 Hathout L, Pope WB, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. Cns Oncology. 4: 247-56. PMID 26095141 DOI: 10.2217/cns.15.16  0.4
2015 Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-Oncology. PMID 26019185 DOI: 10.1093/neuonc/nov083  0.72
2015 Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2166-75. PMID 26014298 DOI: 10.1200/JCO.2014.60.3217  0.72
2015 Hathout L, Ellingson BM, Cloughesy TF, Pope WB. Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. Oncology Reports. 33: 2883-8. PMID 25962999 DOI: 10.3892/or.2015.3926  0.72
2015 Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology. 17: 1051-63. PMID 25934816 DOI: 10.1093/neuonc/nov031  0.72
2015 Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro-Oncology. PMID 25910840 DOI: 10.1093/neuonc/nov064  0.72
2015 Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF. Quantification of nonenhancing tumor burden in gliomas using effective T2 maps derived from dual-echo turbo spin-echo MRI. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25901082 DOI: 10.1158/1078-0432.CCR-14-2862  0.72
2015 Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews. Cancer. 15: 302-10. PMID 25855404 DOI: 10.1038/nrc3918  0.72
2015 Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 122: 497-505. PMID 25773062 DOI: 10.1007/s11060-015-1755-8  0.72
2015 Qiao XJ, Ellingson BM, Kim HJ, Wang DJ, Salamon N, Linetsky M, Sepahdari AR, Jiang B, Tian JJ, Esswein SR, Cloughesy TF, Lai A, Nghiemphu L, Pope WB. Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma. Ajnr. American Journal of Neuroradiology. 36: 672-7. PMID 25542879 DOI: 10.3174/ajnr.A4196  0.72
2015 Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 434-42. PMID 25465392 DOI: 10.1007/s11307-014-0807-3  0.72
2015 Hathout L, Ellingson BM, Cloughesy T, Pope WB. A novel bicompartmental mathematical model of glioblastoma multiforme. International Journal of Oncology. 46: 825-32. PMID 25384756 DOI: 10.3892/ijo.2014.2741  0.72
2015 Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, et al. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-Oncology. 17: 180-8. PMID 25165194 DOI: 10.1093/neuonc/nou154  0.72
2014 Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biology & Medicine. 11: 255-63. PMID 25610711 DOI: 10.7497/j.issn.2095-3941.2014.04.004  0.72
2014 Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 14: 31. PMID 25608485 DOI: 10.1186/s40644-014-0031-z  0.72
2014 Baldock AL, Ahn S, Rockne R, Johnston S, Neal M, Corwin D, Clark-Swanson K, Sterin G, Trister AD, Malone H, Ebiana V, Sonabend AM, Mrugala M, Rockhill JK, Silbergeld DL, ... ... Cloughesy T, et al. Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. Plos One. 9: e99057. PMID 25350742 DOI: 10.1371/journal.pone.0099057  0.72
2014 Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology. 16: vii36-47. PMID 25313237 DOI: 10.1093/neuonc/nou226  0.4
2014 Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro-Oncology. 16: vii2-11. PMID 25313235 DOI: 10.1093/neuonc/nou224  0.4
2014 Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, ... Cloughesy TF, et al. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5808-22. PMID 25224277 DOI: 10.1158/1078-0432.CCR-14-0234  0.72
2014 Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, et al. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology. 16: 1541-6. PMID 24997140 DOI: 10.1093/neuonc/nou083  0.72
2014 Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 2049. PMID 24860870 DOI: 10.1056/NEJMc1402987  0.72
2014 Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 2048-9. PMID 24849088 DOI: 10.1056/NEJMc1403303  0.72
2014 Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3550-9. PMID 24687922 DOI: 10.1158/1078-0432.CCR-13-1440  0.72
2014 Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, ... ... Cloughesy TF, et al. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncology. 16: 815-22. PMID 24627236 DOI: 10.1093/neuonc/nou028  0.72
2014 Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors. European Journal of Nuclear Medicine and Molecular Imaging. 41: 1199-209. PMID 24604590 DOI: 10.1007/s00259-013-2678-2  0.72
2014 Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 709-22. PMID 24552318 DOI: 10.1056/NEJMoa1308345  0.72
2014 Panosyan EH, Wang Y, Xia P, Lee WN, Pak Y, Laks DR, Lin HJ, Moore TB, Cloughesy TF, Kornblum HI, Lasky JL. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Molecular Cancer Research : McR. 12: 694-702. PMID 24505127 DOI: 10.1158/1541-7786.MCR-13-0576  0.72
2014 Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 271: 200-10. PMID 24475840 DOI: 10.1148/radiol.13131305  0.72
2014 Avliyakulov NK, Rajavel KS, Le KM, Guo L, Mirsadraei L, Yong WH, Liau LM, Li S, Lai A, Nghiemphu PL, Cloughesy TF, Linetsky M, Haykinson MJ, Pope WB. C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. Journal of Neuro-Oncology. 117: 53-65. PMID 24473683 DOI: 10.1007/s11060-014-1371-z  0.72
2014 Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16: 567-78. PMID 24470557 DOI: 10.1093/neuonc/not247  0.72
2014 Shabihkhani M, Lucey GM, Wei B, Mareninov S, Lou JJ, Vinters HV, Singer EJ, Cloughesy TF, Yong WH. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clinical Biochemistry. 47: 258-66. PMID 24424103 DOI: 10.1016/j.clinbiochem.2014.01.002  0.72
2014 Zaw TM, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Ellingson BM. Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. Journal of Neuro-Oncology. 116: 601-8. PMID 24395348 DOI: 10.1007/s11060-013-1344-7  0.72
2014 Woodworth DC, Pope WB, Liau LM, Kim HJ, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. Journal of Neuro-Oncology. 116: 551-8. PMID 24318915 DOI: 10.1007/s11060-013-1320-2  0.72
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... Cloughesy TF, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/science.1241328  0.72
2014 Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-Oncology. 16: 603-9. PMID 24305722 DOI: 10.1093/neuonc/not166  0.72
2014 Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncology. 16: 414-20. PMID 24305712 DOI: 10.1093/neuonc/not198  0.72
2014 Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, et al. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro-Oncology. 16: 173-8. PMID 24305708 DOI: 10.1093/neuonc/not229  0.72
2014 Harris RJ, Bookheimer SY, Cloughesy TF, Kim HJ, Pope WB, Lai A, Nghiemphu PL, Liau LM, Ellingson BM. Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. Journal of Neuro-Oncology. 116: 373-9. PMID 24234804 DOI: 10.1007/s11060-013-1304-2  0.72
2014 Ellingson BM, Sahebjam S, Kim HJ, Pope WB, Harris RJ, Woodworth DC, Lai A, Nghiemphu PL, Mason WP, Cloughesy TF. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. Ajnr. American Journal of Neuroradiology. 35: 673-9. PMID 24136647 DOI: 10.3174/ajnr.A3748  0.72
2014 Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annual Review of Pathology. 9: 1-25. PMID 23937436 DOI: 10.1146/annurev-pathol-011110-130324  0.72
2014 White CM, Pope WB, Zaw T, Qiao J, Naeini KM, Lai A, Nghiemphu PL, Wang JJ, Cloughesy TF, Ellingson BM. Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 24: 23-30. PMID 22672084 DOI: 10.1111/j.1552-6569.2012.00703.x  0.72
2014 Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, ... ... Cloughesy TF, et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling Cell Metabolism. DOI: 10.1016/j.cmet.2015.06.009  0.72
2013 Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. Pet Clinics. 8: 201-17. PMID 27157948 DOI: 10.1016/j.cpet.2012.09.002  0.4
2013 Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM. Imaging biomarkers for antiangiogenic therapy in malignant gliomas. Cns Oncology. 2: 33-47. PMID 24570837 DOI: 10.2217/cns.12.29  0.72
2013 Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. Plos One. 8: e80397. PMID 24260384 DOI: 10.1371/journal.pone.0080397  0.72
2013 Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/j.cmet.2013.09.013  0.72
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... Cloughesy TF, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.CCR-13-0527  0.72
2013 Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, ... ... Cloughesy TF, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/j.cmet.2013.04.013  0.72
2013 Mareninov S, De Jesus J, Sanchez DE, Kay AB, Wilson RW, Babic I, Chen W, Telesca D, Lou JJ, Mirsadraei L, Gardner TP, Khanlou N, Vinters HV, Shafa BB, Lai A, ... ... Cloughesy TF, et al. Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. Journal of Neuro-Oncology. 113: 365-73. PMID 23640138 DOI: 10.1007/s11060-013-1135-1  0.72
2013 Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle (Georgetown, Tex.). 12: 1473-4. PMID 23624839 DOI: 10.4161/cc.24747  0.72
2013 Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 970-1. PMID 23565532 DOI: 10.1200/JCO.2012.47.4403  0.72
2013 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, ... ... Cloughesy TF, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.CD-12-0502  0.72
2013 Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Current Neurology and Neuroscience Reports. 13: 347. PMID 23529375 DOI: 10.1007/s11910-013-0347-2  0.72
2013 Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ. Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. International Journal of Radiation Oncology, Biology, Physics. 86: 609-15. PMID 23462418 DOI: 10.1016/j.ijrobp.2013.01.009  0.72
2013 Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, Chowdhury R, Phillips HS, Nghiemphu PL, Behbahanian Y, Ellingson BM. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro-Oncology. 15: 626-34. PMID 23444259 DOI: 10.1093/neuonc/not008  0.72
2013 Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/pnas.1217602110  0.72
2013 Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, ... ... Cloughesy T, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathology (Zurich, Switzerland). 23: 565-73. PMID 23438035 DOI: 10.1111/bpa.12043  0.72
2013 Neal ML, Trister AD, Ahn S, Baldock A, Bridge CA, Guyman L, Lange J, Sodt R, Cloke T, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Research. 73: 2976-86. PMID 23400596 DOI: 10.1158/0008-5472.CAN-12-3588  0.72
2013 Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 152-7. PMID 23377664 DOI: 10.1097/CJI.0b013e3182811ae4  0.72
2013 Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. Plos One. 8: e51951. PMID 23372647 DOI: 10.1371/journal.pone.0051951  0.72
2013 Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan ?, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, ... ... Cloughesy TC, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics. 45: 253-61. PMID 23354438 DOI: 10.1038/ng.2538  0.72
2013 Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, et al. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Targeted Oncology. 8: 117-25. PMID 23345034 DOI: 10.1007/s11523-013-0254-0  0.72
2013 Harris RJ, Cloughesy TF, Pope WB, Godinez S, Natsuaki Y, Nghiemphu PL, Meyer H, Paul D, Behbahanian Y, Lai A, Ellingson BM. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. Journal of Neuro-Oncology. 112: 257-66. PMID 23344788 DOI: 10.1007/s11060-013-1057-y  0.72
2013 Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, ... ... Cloughesy TF, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology. 15: 370-81. PMID 23328811 DOI: 10.1093/neuonc/nos308  0.72
2013 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro-Oncology. 15: 382-90. PMID 23275575 DOI: 10.1093/neuonc/nos314  0.72
2013 Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro-Oncology. 15: 4-27. PMID 23136223 DOI: 10.1093/neuonc/nos273  0.72
2013 Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu KC, Faull KF, Cloughesy T, Liau LM, Lai A. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncology. 15: 57-68. PMID 23115158 DOI: 10.1093/neuonc/nos261  0.72
2013 Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF. Probabilistic radiographic atlas of glioblastoma phenotypes. Ajnr. American Journal of Neuroradiology. 34: 533-40. PMID 22997168 DOI: 10.3174/ajnr.A3253  0.72
2013 Yong WH, Shabihkhani M, Su KC, Wei B, Lucey GM, Mareninov S, Kuo-Bonde LE, Pope WB, Cloughesy TF. Brainstem gliomas: Clinicopathologic features and a practical diagnostic approach for pathologists Pathology Case Reviews. 18: 237-242. DOI: 10.1097/PCR.0b013e3182a9ac78  0.72
2013 Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET parametric response mapping for clinical monitoring and treatment response evaluation in brain tumors Pet Clinics. 8: 201-217. DOI: 10.1016/j.cpet.2012.09.002  0.72
2012 Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, ... ... Cloughesy TF, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology. 14: 1511-8. PMID 23099651 DOI: 10.1093/neuonc/nos264  0.72
2012 Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro-Oncology. 14: 1465-72. PMID 23090985 DOI: 10.1093/neuonc/nos258  0.72
2012 Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, ... ... Cloughesy T, et al. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. Journal of the National Cancer Institute. 104: 1458-69. PMID 22945948 DOI: 10.1093/jnci/djs357  0.72
2012 Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6032-9. PMID 22923449 DOI: 10.1158/1078-0432.CCR-12-1841  0.72
2012 Nghiemphu PL, Lai A, Green RM, Reardon DA, Cloughesy T. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. Journal of Neuro-Oncology. 110: 245-50. PMID 22918789 DOI: 10.1007/s11060-012-0960-y  0.72
2012 Piccioni D, Lai A, Nghiemphu P, Cloughesy T. Bevacizumab as first-line therapy for glioblastoma. Future Oncology (London, England). 8: 929-38. PMID 22894667 DOI: 10.2217/fon.12.81  0.72
2012 Nghiemphu PL, Cloughesy T. Glioblastoma therapy in the elderly: one age does not fit all. The Lancet. Oncology. 13: 857-8. PMID 22877850 DOI: 10.1016/S1470-2045(12)70368-6  0.72
2012 Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology. 14: 1079-89. PMID 22711609 DOI: 10.1093/neuonc/nos141  0.72
2012 Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-Oncology. 14: 761-7. PMID 22661585 DOI: 10.1093/neuonc/nos065  0.72
2012 Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3258-63. PMID 22649140 DOI: 10.1200/JCO.2011.39.8420  0.72
2012 Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, ... ... Cloughesy TF, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery. 2: 458-71. PMID 22588883 DOI: 10.1158/2159-8290.CD-11-0284  0.72
2012 Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. The Lancet. Oncology. 13: e196-204. PMID 22554547 DOI: 10.1016/S1470-2045(11)70406-5  0.72
2012 Mong S, Ellingson BM, Nghiemphu PL, Kim HJ, Mirsadraei L, Lai A, Yong W, Zaw TM, Cloughesy TF, Pope WB. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. Ajnr. American Journal of Neuroradiology. 33: 1763-70. PMID 22538078 DOI: 10.3174/ajnr.A3053  0.72
2012 Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, ... ... Cloughesy T, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology. 108: 491-8. PMID 22426926 DOI: 10.1007/s11060-012-0847-y  0.72
2012 Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/s00280-012-1854-6  0.72
2012 Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 393-8. PMID 22323780 DOI: 10.2967/jnumed.111.095711  0.72
2012 Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Ajnr. American Journal of Neuroradiology. 33: 1349-55. PMID 22322613 DOI: 10.3174/ajnr.A2950  0.72
2012 Ellingson BM, Zaw T, Cloughesy TF, Naeini KM, Lalezari S, Mong S, Lai A, Nghiemphu PL, Pope WB. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. Journal of Magnetic Resonance Imaging : Jmri. 35: 1472-7. PMID 22281731 DOI: 10.1002/jmri.23600  0.72
2012 Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, Liau LM, Pope WB. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro-Oncology. 14: 333-43. PMID 22270220 DOI: 10.1093/neuonc/nor220  0.72
2012 Pope WB, Mirsadraei L, Lai A, Eskin A, Qiao J, Kim HJ, Ellingson B, Nghiemphu PL, Kharbanda S, Soriano RH, Nelson SF, Yong W, Phillips HS, Cloughesy TF. Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. Ajnr. American Journal of Neuroradiology. 33: 1059-64. PMID 22268080 DOI: 10.3174/ajnr.A2917  0.72
2012 Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 29-36. PMID 22159180 DOI: 10.2967/jnumed.111.092387  0.72
2012 Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology. 38: 271-91. PMID 22098029 DOI: 10.1111/j.1365-2990.2011.01238.x  0.72
2012 Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, ... ... Cloughesy TF, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Journal of Neuro-Oncology. 107: 197-205. PMID 22015945 DOI: 10.1007/s11060-011-0737-8  0.72
2012 Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Current Topics in Microbiology and Immunology. 355: 135-69. PMID 22015553 DOI: 10.1007/82_2011_178  0.72
2012 Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 59: 908-16. PMID 22001163 DOI: 10.1016/j.neuroimage.2011.09.076  0.72
2012 Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemotherapy and Pharmacology. 69: 281-7. PMID 21984222 DOI: 10.1007/s00280-011-1754-1  0.72
2012 Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of Neuro-Oncology. 106: 147-53. PMID 21739168 DOI: 10.1007/s11060-011-0650-1  0.72
2012 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 106: 111-9. PMID 21706273 DOI: 10.1007/s11060-011-0638-x  0.72
2012 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine. 67: 237-45. PMID 21702063 DOI: 10.1002/mrm.23003  0.72
2012 Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, DeAngelis LM. Response to C. Massard et al Journal of Clinical Oncology. 30: 563-564. DOI: 10.1200/JCO.2011.40.1513  0.72
2012 Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Gregory Cairncross J, Urgoiti GBR, Wen PY, Ligon KL, Schiff D, et al. Response to Weltman and Fleury Malheiros, re Lassman et al. Neuro-Oncology. 14: 677-678. DOI: 10.1093/neuonc/nos136  0.72
2011 Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, ... ... Cloughesy TF, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.CD-11-0124  0.72
2011 Cloughesy T. The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. Seminars in Oncology. 38: S11-20. PMID 22078643 DOI: 10.1053/j.seminoncol.2011.09.007  0.72
2011 Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, ... ... Cloughesy TF, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discovery. 1: 442-56. PMID 22059152 DOI: 10.1158/2159-8290.CD-11-0102  0.72
2011 Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, ... ... Cloughesy T, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4482-90. PMID 22025148 DOI: 10.1200/JCO.2010.33.8715  0.72
2011 Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel PS, ... Cloughesy TF, et al. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Molecular Cancer Research : McR. 9: 1668-85. PMID 22013079 DOI: 10.1158/1541-7786.MCR-10-0563  0.72
2011 Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6553-62. PMID 21868765 DOI: 10.1158/1078-0432.CCR-10-3290  0.72
2011 Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 1151-61. PMID 21856685 DOI: 10.1093/neuonc/nor079  0.72
2011 Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-Oncology. 13: 1118-24. PMID 21813511 DOI: 10.1093/neuonc/nor110  0.72
2011 Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, et al. It is time to include patients with brain tumors in phase I trials in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3211-3. PMID 21768451 DOI: 10.1200/JCO.2011.36.6328  0.72
2011 Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-Oncology. 13: 649-59. PMID 21636710 DOI: 10.1093/neuonc/nor040  0.72
2011 de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4872-81. PMID 21632852 DOI: 10.1158/1078-0432.CCR-11-0271  0.72
2011 de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2689-95. PMID 21606416 DOI: 10.1200/JCO.2010.34.1636  0.72
2011 Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 660-8. PMID 21558074 DOI: 10.1093/neuonc/nor024  0.72
2011 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. High order diffusion tensor imaging in human glioblastoma. Academic Radiology. 18: 947-54. PMID 21536466 DOI: 10.1016/j.acra.2011.02.020  0.72
2011 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 105: 91-101. PMID 21442275 DOI: 10.1007/s11060-011-0567-8  0.72
2011 Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in Therapy. 28: 334-40. PMID 21432029 DOI: 10.1007/s12325-011-0007-3  0.72
2011 Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. Ajnr. American Journal of Neuroradiology. 32: 882-9. PMID 21330401 DOI: 10.3174/ajnr.A2385  0.72
2011 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 401-9. PMID 21324937 DOI: 10.1093/neuonc/noq206  0.72
2011 Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 13: 353-61. PMID 21310734 DOI: 10.1093/neuonc/noq203  0.72
2011 Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncology. 13: 437-46. PMID 21297127 DOI: 10.1093/neuonc/noq198  0.72
2011 Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 76: 432-7. PMID 21282590 DOI: 10.1212/WNL.0b013e31820a0a8a  0.72
2011 Kay AB, Estrada DK, Mareninov S, Silver SS, Magyar CE, Dry SM, Cloughesy TF, Yong WH. Considerations for uniform and accurate biospecimen labelling in a biorepository and research environment. Journal of Clinical Pathology. 64: 634-6. PMID 21217091 DOI: 10.1136/jcp.2010.080655  0.72
2011 Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6-11. PMID 21208902 DOI: 10.1158/1078-0432.CCR-09-2268  0.72
2011 Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, ... ... Cloughesy T, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 142-8. PMID 21135282 DOI: 10.1200/JCO.2010.30.2729  0.72
2011 Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 143-51. PMID 21084434 DOI: 10.1093/neuonc/noq151  0.72
2011 Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, ... ... Cloughesy TF, et al. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics. 81: 1422-7. PMID 20934264 DOI: 10.1016/j.ijrobp.2010.07.1997  0.72
2011 Solis OE, Mehta RI, Lai A, Mehta RI, Farchoukh LO, Green RM, Cheng JC, Natarajan S, Vinters HV, Cloughesy T, Yong WH. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. Journal of Neuro-Oncology. 102: 477-84. PMID 20872044 DOI: 10.1007/s11060-010-0335-1  0.72
2010 Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmacogenomics and Personalized Medicine. 3: 79-85. PMID 23226044  0.72
2010 Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. The Oncologist. 15: 1329-34. PMID 21147867 DOI: 10.1634/theoncologist.2010-0105  0.72
2010 Cloughesy T. FDA accelerated approval benefits glioblastoma. The Lancet. Oncology. 11: 1120. PMID 21126686 DOI: 10.1016/S1470-2045(10)70269-2  0.72
2010 Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1532-8. PMID 20847166 DOI: 10.2967/jnumed.110.078592  0.72
2010 Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology. 12: 1061-70. PMID 20615922 DOI: 10.1093/neuonc/noq072  0.72
2010 Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel PS, Moore TB, Kornblum HI. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatric Blood & Cancer. 55: 644-51. PMID 20589659 DOI: 10.1002/pbc.22627  0.72
2010 Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC, Swanson KR. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Physics in Medicine and Biology. 55: 3271-85. PMID 20484781 DOI: 10.1088/0031-9155/55/12/001  0.72
2010 Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncology. 12: 882-9. PMID 20472883 DOI: 10.1093/neuonc/noq052  0.72
2010 Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 720-7. PMID 20395318 DOI: 10.2967/jnumed.109.068361  0.72
2010 Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, ... ... Cloughesy TF, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America. 107: 6459-64. PMID 20308550 DOI: 10.1073/pnas.0911188107  0.72
2010 Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1963-72. PMID 20231676 DOI: 10.1200/JCO.2009.26.3541  0.72
2010 Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology. 12: 95-103. PMID 20150372 DOI: 10.1093/neuonc/nop015  0.72
2010 Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro-Oncology. 12: 87-94. PMID 20150371 DOI: 10.1093/neuonc/nop017  0.72
2010 Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle (Georgetown, Tex.). 9: 211-2. PMID 20023392 DOI: 10.4161/cc.9.2.10540  0.72
2010 Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodríguez-Ponce MI, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. Journal of Neurosurgery. 113: 301-9. PMID 20020841 DOI: 10.3171/2009.11.JNS091052  0.72
2010 Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathology (Zurich, Switzerland). 20: 751-62. PMID 20015288 DOI: 10.1111/j.1750-3639.2009.00356.x  0.72
2010 Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, ... ... Cloughesy TF, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics. 42: 77-82. PMID 19946270 DOI: 10.1038/ng.491  0.72
2010 Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. Journal of Neuro-Oncology. 96: 359-67. PMID 19655089 DOI: 10.1007/s11060-009-9983-4  0.72
2010 Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology. 96: 211-7. PMID 19562255 DOI: 10.1007/s11060-009-9948-7  0.72
2010 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Reply to W. Wick et al Journal of Clinical Oncology. 28: e190-e192. DOI: 10.1200/JCO.2009.26.9472  0.72
2009 Tran A, Escovedo C, Migdall-Wilson J, Chou AP, Chen W, Cloughesy T, Nelson S, Lai A. In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays. Frontiers in Neuroscience. 3: 57. PMID 20582289 DOI: 10.3389/neuro.15.005.2009  0.4
2009 Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, ... ... Cloughesy TF, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science Signaling. 2: ra82. PMID 20009104 DOI: 10.1126/scisignal.2000446  0.72
2009 Wang CH, Rockhill JK, Mrugala M, Peacock DL, Lai A, Jusenius K, Wardlaw JM, Cloughesy T, Spence AM, Rockne R, Alvord EC, Swanson KR. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Research. 69: 9133-40. PMID 19934335 DOI: 10.1158/0008-5472.CAN-08-3863  0.72
2009 Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB. Bevacizumab for recurrent ependymoma. Neurology. 73: 1677-80. PMID 19917990 DOI: 10.1212/WNL.0b013e3181c1df34  0.72
2009 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4733-40. PMID 19720927 DOI: 10.1200/JCO.2008.19.8721  0.72
2009 Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Cloughesy TF, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.CAN-09-0347  0.72
2009 Iwanami A, Cloughesy TF, Mischel PS. Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes & Development. 23: 1699-704. PMID 19651981 DOI: 10.1101/gad.1832909  0.72
2009 Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proceedings of the National Academy of Sciences of the United States of America. 106: 12932-7. PMID 19625624 DOI: 10.1073/pnas.0906606106  0.72
2009 McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 16: 44-54. PMID 19573811 DOI: 10.1016/j.ccr.2009.05.009  0.72
2009 Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 252: 182-9. PMID 19561256 DOI: 10.1148/radiol.2521081534  0.72
2009 Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 500-12. PMID 19560740 DOI: 10.1016/j.nurt.2009.04.008  0.72
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/pnas.0900571106  0.72
2009 Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. Journal of Neuro-Oncology. 94: 1-19. PMID 19468690 DOI: 10.1007/s11060-009-9919-z  0.72
2009 Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (Dayton, Ohio). 27: 980-7. PMID 19353526 DOI: 10.1002/stem.15  0.72
2009 Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 72: 1217-22. PMID 19349600 DOI: 10.1212/01.wnl.0000345668.03039.90  0.72
2009 Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010  0.72
2009 Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. Journal of Neuro-Oncology. 91: 183-9. PMID 18850068 DOI: 10.1007/s11060-008-9705-3  0.72
2009 Remington M, Chtchetinin J, Ancheta K, Nghiemphu PL, Cloughesy T, Lai A. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro-Oncology. 11: 22-32. PMID 18812520 DOI: 10.1215/15228517-2008-080  0.72
2009 Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of Neuro-Oncology. 91: 175-82. PMID 18797818 DOI: 10.1007/s11060-008-9693-3  0.72
2009 Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. European Journal of Radiology. 71: 242-8. PMID 18511228 DOI: 10.1016/j.ejrad.2008.04.018  0.72
2008 Taira RK, Taira R, Bui A, Bui AA, Hsu W, Bashyam V, Dube S, Watt E, Andrada L, El-Saden S, Cloughesy T, Kangarloo H. A tool for improving the longitudinal imaging characterization for neuro-oncology cases. Amia ... Annual Symposium Proceedings / Amia Symposium. Amia Symposium. 712-6. PMID 18999139  0.72
2008 Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5610-7. PMID 18981465 DOI: 10.1200/JCO.2008.16.7510  0.72
2008 Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. Bmc Medical Genomics. 1: 52. PMID 18940004 DOI: 10.1186/1755-8794-1-52  0.72
2008 Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 249: 268-77. PMID 18796682 DOI: 10.1148/radiol.2491072000  0.72
2008 Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. The New England Journal of Medicine. 359: 539-41. PMID 18669440 DOI: 10.1056/NEJMc0804818  0.72
2008 Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro-Oncology. 10: 631-42. PMID 18559968 DOI: 10.1215/15228517-2008-021  0.72
2008 Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology. 10: 355-60. PMID 18436627 DOI: 10.1215/15228517-2008-009  0.72
2008 Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB. Time course of imaging changes of GBM during extended bevacizumab treatment. Journal of Neuro-Oncology. 88: 339-47. PMID 18389177 DOI: 10.1007/s11060-008-9573-x  0.72
2008 Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 10: 162-70. PMID 18356283 DOI: 10.1215/15228517-2007-062  0.72
2008 Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. International Journal of Radiation Oncology, Biology, Physics. 71: 1372-80. PMID 18355978 DOI: 10.1016/j.ijrobp.2007.11.068  0.72
2008 Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, ... ... Cloughesy TF, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 488-93. PMID 18223223 DOI: 10.1158/1078-0432.CCR-07-1966  0.72
2008 Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/journal.pmed.0050008  0.72
2008 Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, ... ... Cloughesy TF, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. Journal of Neuroscience Research. 86: 48-60. PMID 17722061 DOI: 10.1002/jnr.21471  0.72
2008 Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemotherapy and Pharmacology. 61: 1059-67. PMID 17694310 DOI: 10.1007/s00280-007-0556-y  0.72
2008 Dube S, Corso JJ, Yuille A, Cloughesy TF, El-Saden S, Sinha U. Hierarchical segmentation of malignant Gliomas via integrated contextual filter response Progress in Biomedical Optics and Imaging - Proceedings of Spie. 6914. DOI: 10.1117/12.770769  0.72
2007 Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7401-6. PMID 18094423 DOI: 10.1158/1078-0432.CCR-07-0781  0.72
2007 Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, ... ... Cloughesy TF, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/pnas.0710052104  0.72
2007 Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, et al. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7133-8. PMID 18056194 DOI: 10.1158/1078-0432.CCR-07-0874  0.72
2007 Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4714-21. PMID 17947718 DOI: 10.1200/JCO.2006.10.5825  0.72
2007 Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA kinetics in brain tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1651-61. PMID 17873130 DOI: 10.2967/jnumed.106.039321  0.72
2007 Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2592-8. PMID 17473188 DOI: 10.1158/1078-0432.CCR-06-2772  0.72
2007 Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-fluorothymidine kinetics of malignant brain tumors. European Journal of Nuclear Medicine and Molecular Imaging. 34: 1003-11. PMID 17295039 DOI: 10.1007/s00259-006-0354-5  0.72
2007 Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Cloughesy TF, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/ng1975  0.72
2007 Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 378-81. PMID 17255257 DOI: 10.1158/1078-0432.CCR-06-1992  0.72
2007 Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of Neuro-Oncology. 81: 271-7. PMID 17031561 DOI: 10.1007/s11060-006-9225-y  0.72
2007 Dube S, Corso JJ, Cloughesy TF, El-Saden S, Yuille AL, Sinha U. Automated MR image processing and analysis of malignant brain tumors: Enabling technology for data mining Aip Conference Proceedings. 953: 64-84. DOI: 10.1063/1.2817354  0.72
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Cloughesy T, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/journal.pmed.0030485  0.72
2006 Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, ... ... Cloughesy TF, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proceedings of the National Academy of Sciences of the United States of America. 103: 17402-7. PMID 17090670 DOI: 10.1073/pnas.0608396103  0.72
2006 Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Molecular Cancer Research : McR. 4: 607-19. PMID 16966431 DOI: 10.1158/1541-7786.MCR-06-0005  0.72
2006 Mischel PS, Cloughesy T. Using molecular information to guide brain tumor therapy. Nature Clinical Practice. Neurology. 2: 232-3. PMID 16932555 DOI: 10.1038/ncpneuro0145  0.72
2006 Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4899-907. PMID 16914578 DOI: 10.1158/1078-0432.CCR-06-0773  0.72
2006 Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.CAN-04-4392  0.72
2006 Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3651-6. PMID 16877733 DOI: 10.1200/JCO.2006.06.2323  0.72
2006 Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 904-11. PMID 16741298  0.72
2006 Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 66: 1258-60. PMID 16636248 DOI: 10.1212/01.wnl.0000208958.29600.87  0.72
2006 Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncology. 8: 189-93. PMID 16533878 DOI: 10.1215/15228517-2005-010  0.32
2006 Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Research. 66: 159-67. PMID 16397228 DOI: 10.1158/0008-5472.CAN-05-0077  0.72
2005 Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. Ajnr. American Journal of Neuroradiology. 26: 2466-74. PMID 16286386  0.72
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Cloughesy TF, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/NEJMoa051918  0.72
2005 Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5515-25. PMID 16061868 DOI: 10.1158/1078-0432.CCR-05-0464  0.72
2005 Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23: 357-61. PMID 16012795 DOI: 10.1007/s10637-005-1444-0  0.32
2005 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 945-52. PMID 15937304  0.72
2005 Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. The Journal of Biological Chemistry. 280: 26953-64. PMID 15908427 DOI: 10.1074/jbc.M502614200  0.72
2005 Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Research. Molecular Brain Research. 136: 99-103. PMID 15893592 DOI: 10.1016/j.molbrainres.2005.01.017  0.72
2004 Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biology & Therapy. 3: 1243-9. PMID 15611621  0.72
2004 Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4282-9. PMID 15514370 DOI: 10.1200/JCO.2004.09.096  0.72
2004 Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Reviews. Neuroscience. 5: 782-92. PMID 15378038 DOI: 10.1038/nrn1518  0.72
2004 Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. Gene expression profiling of gliomas strongly predicts survival. Cancer Research. 64: 6503-10. PMID 15374961 DOI: 10.1158/0008-5472.CAN-04-0452  0.72
2004 Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Investigational New Drugs. 22: 427-35. PMID 15292713 DOI: 10.1023/B:DRUG.0000036685.72140.03  0.32
2004 Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, Goldman J. Prediction of neurocognitive outcome in adult brain tumor patients. Journal of Neuro-Oncology. 67: 245-53. PMID 15072475 DOI: 10.1023/B:NEON.0000021900.29176.58  0.72
2004 Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. Journal of Neuro-Oncology. 66: 365-75. PMID 15015670 DOI: 10.1023/B:NEON.0000014549.77646.f6  0.72
2004 Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 23: 1283-90. PMID 14961077 DOI: 10.1038/sj.onc.1207244  0.72
2004 Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncology. 6: 44-54. PMID 14769140 DOI: 10.1215/S1152851703000292  0.72
2004 Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Laboratory Investigation; a Journal of Technical Methods and Pathology. 84: 8-20. PMID 14631378 DOI: 10.1038/sj.labinvest.3700003  0.72
2003 Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 22: 4918-23. PMID 12894235 DOI: 10.1038/sj.onc.1206753  0.72
2003 Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biology & Therapy. 2: 242-7. PMID 12878856  0.72
2003 Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Research. 63: 2742-6. PMID 12782577  0.72
2003 Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 22: 2361-73. PMID 12700671 DOI: 10.1038/sj.onc.1206344  0.72
2003 Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathology (Zurich, Switzerland). 13: 52-61. PMID 12580545  0.72
2002 Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2894-901. PMID 12231534  0.72
2002 Alger JR, Frew AJ, Cloughesy TF, Del Vecchio W, Villablanca JP, Curran JG. Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging. Magnetic Resonance in Medicine. 48: 411-8. PMID 12210904 DOI: 10.1002/mrm.10239  0.72
2002 Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J. Predicting major depression in brain tumor patients. Psycho-Oncology. 11: 230-8. PMID 12112483 DOI: 10.1002/pon.562  0.72
2002 Robins HI, Chang SM, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn JG, Cloughesy T, Junck L, Mehta M. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro-Oncology. 4: 109-14. PMID 11916502  0.32
2001 Haney SM, Thompson PM, Cloughesy TF, Alger JR, Frew AJ, Torres-Trejo A, Mazziotta JC, Toga AW. Mapping therapeutic response in a patient with malignant glioma. Journal of Computer Assisted Tomography. 25: 529-36. PMID 11473181 DOI: 10.1097/00004728-200107000-00004  0.72
2001 Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-Oncology. 3: 46-54. PMID 11305417  0.72
2001 Gobin YP, Cloughesy TF, Chow KL, Duckwiler GR, Sayre JW, Milanese K, Viñuela F. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology. 218: 724-32. PMID 11230646 DOI: 10.1148/radiology.218.3.r01mr41724  0.72
2001 Haney SM, Thompson PM, Cloughesy TF, Alger JR, Toga AW. Tracking tumor growth rates in patients with malignant gliomas: a test of two algorithms. Ajnr. American Journal of Neuroradiology. 22: 73-82. PMID 11158891  0.72
2000 Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel PS, Belldegrun A, Cloughesy TF. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurgical Focus. 9: e8. PMID 16817691  0.72
2000 Gupta RK, Cloughesy TF, Sinha U, Garakian J, Lazareff J, Rubino G, Rubino L, Becker DP, Vinters HV, Alger JR. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. Journal of Neuro-Oncology. 50: 215-26. PMID 11263501 DOI: 10.1023/A:1006431120031  0.72
2000 Chow KL, Gobin YP, Cloughesy T, Sayre JW, Villablanca JP, Viñuela F. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. Ajnr. American Journal of Neuroradiology. 21: 471-8. PMID 10730637  0.72
1999 Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. Journal of Neurosurgery. 90: 1115-24. PMID 10350260 DOI: 10.3171/jns.1999.90.6.1115  0.72
1999 Gupta RK, Sinha U, Cloughesy TF, Alger JR. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 41: 2-7. PMID 10025604 DOI: 10.1002/(SICI)1522-2594(199901)41:1<2::AID-MRM2>3.0.CO;2-Y  0.72
1999 Cloughesy TF, Black KL, Gobin YP, Farahani K, Nelson G, Villablanca P, Kabbinavar F, Viñeula F, Wortel CH. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery. 44: 270-8; discussion 27. PMID 9932880  0.4
1998 Cannestra AF, Black KL, Martin NA, Cloughesy T, Burton JS, Rubinstein E, Woods RP, Toga AW. Topographical and temporal specificity of human intraoperative optical intrinsic signals. Neuroreport. 9: 2557-63. PMID 9721932  0.4
1997 Cloughesy TF, Gobin YP, Black KL, Viñuela F, Taft F, Kadkhoda B, Kabbinavar F. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. Journal of Neuro-Oncology. 35: 121-31. PMID 9266448  0.4
1997 Cloughesy TF, Woods RP, Black KL, Couldwell WT, Law RE, Hinton DR. Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. Journal of Neuro-Oncology. 35: 39-45. PMID 9266439  0.4
1997 Black KL, Cloughesy T, Huang SC, Gobin YP, Zhou Y, Grous J, Nelson G, Farahani K, Hoh CK, Phelps M. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. Journal of Neurosurgery. 86: 603-9. PMID 9120622 DOI: 10.3171/jns.1997.86.4.0603  0.4
1995 Cloughesy TF, Black KL. Pharmacological blood-brain barrier modification for selective drug delivery. Journal of Neuro-Oncology. 26: 125-32. PMID 8787854  0.4
1995 Geschwind DH, Iacoboni M, Mega MS, Zaidel DW, Cloughesy T, Zaidel E. Alien hand syndrome: interhemispheric motor disconnection due to a lesion in the midbody of the corpus callosum. Neurology. 45: 802-8. PMID 7723974  0.72
1993 Cloughesy TF, Nuwer MR, Hoch D, Vinuela F, Duckwiler G, Martin N. Monitoring carotid test occlusions with continuous EEG and clinical examination. Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society. 10: 363-9. PMID 8408601  0.72
1992 Nuwer MR, Banoczi WR, Cloughesy TF, Hoch DB, Peacock W, Levesque MF, Black KL, Martin NA, Becker DP. Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room. Brain Topography. 5: 53-8. PMID 1463660 DOI: 10.1007/BF01129970  0.72
Show low-probability matches.